Literature DB >> 16877463

Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis.

L Beretta1, A Santaniello, A Lemos, M Masciocchi, R Scorza.   

Abstract

OBJECTIVES: Interstitial lung disease (ILD) profoundly affects the health-related quality of life (HRQoL) in patients with systemic sclerosis (SSc). We tested the validity of the Saint George's Respiratory Questionnaire (SGRQ), a lung-specific HRQoL-evaluation tool, in a population of SSc patients with ILD.
METHODS: Twenty-eight consecutive SSc patients with a restrictive pulmonary involvement, defined as a forced vital capacity <80% of the predicted, with no pulmonary hypertension were considered. All the patients filled in the Medical Research Council (MRC) scale for perceived breathlessness, the SGRQ and the Disability Index of the Health Assessment Questionnaire (HAQ DI), and underwent evaluation with complete pulmonary function testing (PFT), 6-minute walk distance (6MWD) and high-resolution computed tomography (HRCT).
RESULTS: The SGRQ 'activity' scores inversely correlated with the 6MWD (r = -0.86, P < 0.001) and forced vital capacity percentage of predicted values (r = -0.47) and directly correlated with HRCT (r = 0.41, P < 0.05), MRC (rho = 0.64, P < 0.001) or HAQ DI scores (r = 0.62, P < 0.001), independently of disease duration or subset. On the contrary, HAQ DI scores were influenced by those variables and corrected correlations with 6MWD (r = 0.56, P < 0.001) or HRCT scores (r = 0.36, P = NS) were less strong than those observed with the SGRQ.
CONCLUSIONS: The SGRQ, although not specifically designed for scleroderma, is a valid respiratory-specific questionnaire for the evaluation of HRQoL in patients with SSc-related ILD. The SGRQ performs better in relation to exercise capacity and lung imaging than other non-respiratory-specific questionnaires widely used in scleroderma studies. Further studies are needed to address its ability to assess changes over time or in response to therapy.

Entities:  

Mesh:

Year:  2006        PMID: 16877463     DOI: 10.1093/rheumatology/kel221

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  17 in total

1.  Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

Authors:  Beth Wallace; Suzanne Kafaja; Daniel E Furst; Veronica J Berrocal; Peter A Merkel; James R Seibold; Maureen D Mayes; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2015-02-09       Impact factor: 7.580

Review 2.  Oral Chinese herbal medicine for improvement of quality of life in patients with stable chronic obstructive pulmonary disease: a systematic review.

Authors:  Xuedong An; Anthony Lin Zhang; Brian H May; Lin Lin; Yinji Xu; Charlie Changli Xue
Journal:  J Altern Complement Med       Date:  2012-07-17       Impact factor: 2.579

3.  Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form.

Authors:  Monique Hinchcliff; Jennifer L Beaumont; Krishna Thavarajah; John Varga; Anh Chung; Sofia Podlusky; Mary Carns; Rowland W Chang; David Cella
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

4.  Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.

Authors:  Donald P Tashkin; Elizabeth R Volkmann; Chi-Hong Tseng; Michael D Roth; Dinesh Khanna; Daniel E Furst; Philip J Clements; Arthur Theodore; Suzanne Kafaja; Grace Hyun Kim; Jonathan Goldin; Edgar Ariolla; Robert M Elashoff
Journal:  Chest       Date:  2016-12-22       Impact factor: 9.410

5.  Sleep disruption as a predictor of quality of life among patients in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS).

Authors:  Michelle R Zeidler; Jennifer L Martin; Eric C Kleerup; Hartmut Schneider; Michael N Mitchell; Nadia N Hansel; Krishna Sundar; Helena Schotland; Robert C Basner; J Michael Wells; Jerry A Krishnan; Gerard J Criner; Stephanie Cristenson; Samuel Krachman; M Safwan Badr
Journal:  Sleep       Date:  2018-05-01       Impact factor: 5.849

6.  Determinants of health related quality of life in a sample of patients with chronic obstructive pulmonary disease in Nigeria using the St. George's respiratory questionnaire.

Authors:  D O Obaseki; G E Erhabor; O F Awopeju; J E Obaseki; O O Adewole
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 7.  Treatment of Sarcoidosis.

Authors:  Robert P Baughman; Elyse E Lower
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

8.  [Medico-legal assessment of systemic sclerosis].

Authors:  M Graninger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

9.  An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility.

Authors:  Chiara M Antonioli; Giovanni Bua; Anna Frigè; Katia Prandini; Sara Radici; Mirko Scarsi; Elisabetta Danieli; Andrea Malvicini; Paolo Airo
Journal:  Clin Rheumatol       Date:  2008-09-16       Impact factor: 2.980

10.  Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease.

Authors:  Cristine E Berry; M Bradley Drummond; MeiLan K Han; Daner Li; Cathy Fuller; Andrew H Limper; Fernando J Martinez; Marvin I Schwarz; Frank C Sciurba; Robert A Wise
Journal:  Chest       Date:  2012-09       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.